MIRA Logo

MIRA Pharmaceuticals, Inc. - Common Stock (MIRA) Stock Forecast & Price Prediction

Live MIRA Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Drug Manufacturers - General

$1.16

-0.03 (-2.52%)

12 Month Price Forecast For MIRA

$1.16
Current Price
$19.21M
Market Cap
1 Ratings
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to MIRA Price Forecasts

+1,430.2%
To High Target of $17.75
+988.4%
To Median Target of $12.63
+546.6%
To Low Target of $7.50

MIRA Price Momentum

+0.9%
1 Week Change
-2.5%
1 Month Change
+12.6%
1 Year Change
+1.8%
Year-to-Date Change
-76.8%
From 52W High of $5.01
+127.5%
From 52W Low of $0.51

๐Ÿค” Considering MIRA Pharmaceuticals (MIRA)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 4:08 AM UTC

MIRA Analyst Ratings & Price Targets

Based on our analysis of 2 Wall Street analysts, MIRA has a bullish consensus with a median price target of $12.63 (ranging from $7.50 to $17.75). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.16, the median forecast implies a 988.4% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MIRA Analyst Consensus

1
Buy
0
Hold
0
Sell

MIRA Price Target Range

Low
$7.50
Average
$12.63
High
$17.75
Current: $1.16

Latest MIRA Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MIRA.

Date Firm Analyst Rating Change Price Target
Sep 30, 2024 Rodman & Renshaw Elemer Piros Buy Initiates $17.00
Aug 5, 2024 Ascendiant Capital Edward Woo Buy Initiates $11.00

Stocks Similar to MIRA Pharmaceuticals, Inc. - Common Stock

The following stocks are similar to MIRA Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

MIRA Pharmaceuticals, Inc. - Common Stock (MIRA) Financial Data

MIRA Pharmaceuticals, Inc. - Common Stock has a market capitalization of $19.21M with a P/E ratio of -1.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -192.3%.

Valuation Metrics

Market Cap $19.21M
Enterprise Value $15.56M
P/E Ratio -1.8x
PEG Ratio -2.4x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +21.6%
Current Ratio 6.1x
Debt/Equity 0.0x
ROE -192.3%
ROA -81.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

MIRA Pharmaceuticals, Inc. - Common Stock logo

MIRA Pharmaceuticals, Inc. - Common Stock (MIRA) Company Overview

About MIRA Pharmaceuticals, Inc. - Common Stock

What They Do

Develops treatments for neurological disorders.

Business Model

MIRA Pharmaceuticals focuses on developing innovative therapies for neurological and neuropsychiatric disorders. The company generates potential revenue through the development and commercialization of its proprietary drugs, including Ketamir-2 for depression-related conditions and MIRA-55 for anxiety and cognitive decline.

Additional Information

The company is in the pre-clinical stage, indicating early development of its drug candidates. MIRA Pharmaceuticals holds exclusive rights in key North American markets, which may enhance its competitive positioning. Established in 2020 and based in Miami, Florida, the company is positioned in a growing market for mental health therapies.

Company Information

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

0

CEO

Mr. Erez Aminov

Country

United States

IPO Year

2023

MIRA Pharmaceuticals, Inc. - Common Stock (MIRA) Latest News & Analysis

MIRA stock latest news image
Quick Summary

MIRA Pharmaceuticals (NASDAQ:MIRA) has submitted an IND application to the FDA for Ketamir-2, a novel oral ketamine analog aimed at treating neuropathic pain, advancing its lead drug candidate.

Why It Matters

MIRA Pharmaceuticals' IND submission for Ketamir-2 signals progress in drug development, potentially enhancing market confidence and stock performance as they pursue FDA approval for neuropathic pain treatment.

Source: Accesswire
Market Sentiment: Neutral
MIRA stock latest news image
Quick Summary

MIRA Pharmaceuticals completed its GLP preclinical safety program for Ketamir-2, confirming no adverse findings and advancing toward an IND application by year-end 2024.

Why It Matters

MIRA Pharmaceuticalsโ€™ successful safety validation for Ketamir-2 and upcoming IND application could attract investor interest, signaling potential growth and advancement in neuropathic pain treatments.

Source: Accesswire
Market Sentiment: Neutral
MIRA stock latest news image
Quick Summary

MIRA Pharmaceuticals (NASDAQ:MIRA) plans to begin a Phase I/IIa trial of Ketamir-2 in Q1 2025 at CHDR in the Netherlands, with early results anticipated in late 2025.

Why It Matters

MIRA's transition to clinical-stage with a promising drug candidate could enhance its market value, attract investment, and indicate potential revenue streams from breakthrough treatments.

Source: Accesswire
Market Sentiment: Neutral
MIRA stock latest news image
Quick Summary

MIRA Pharmaceuticals (NASDAQ:MIRA) reports preclinical results showing Ketamir-2 is 60% more effective than gabapentin for chemotherapy-induced pain. Results will be shared at the Pain Therapeutics Summit.

Why It Matters

MIRA Pharmaceuticals' promising results for Ketamir-2 could lead to significant market share in pain management, impacting stock performance and investor sentiment positively.

Source: Accesswire
Market Sentiment: Neutral
MIRA stock latest news image
Quick Summary

MIRA Pharmaceuticals' novel oral ketamine analog, Ketamir-2, has demonstrated superior pain relief compared to Gabapentin and Pregabalin, potentially offering a non-opioid alternative for neuropathic pain.

Why It Matters

MIRA Pharmaceuticals' Ketamir-2 outperforming established pain treatments could disrupt the market, attract investment, and enhance the company's valuation amid rising demand for non-opioid solutions.

Source: Accesswire
Market Sentiment: Neutral
MIRA stock latest news image
Quick Summary

MIRA Pharmaceuticals announced preclinical results showing Ketamir-2 achieved 100% reversal of neuropathic pain. Results will be presented at the Pain Therapeutics Summit on October 28-29, 2024.

Why It Matters

MIRA Pharmaceuticals' announcement of Ketamir-2's 100% efficacy in reversing neuropathic pain could attract investor interest, signaling potential for significant market impact and future revenue.

Source: Accesswire
Market Sentiment: Neutral

Frequently Asked Questions About MIRA Stock

What is MIRA Pharmaceuticals, Inc. - Common Stock's (MIRA) stock forecast for 2025?

Based on our analysis of 2 Wall Street analysts, MIRA Pharmaceuticals, Inc. - Common Stock (MIRA) has a median price target of $12.63. The highest price target is $17.75 and the lowest is $7.50.

Is MIRA stock a good investment in 2025?

According to current analyst ratings, MIRA has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.16. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MIRA stock?

Wall Street analysts predict MIRA stock could reach $12.63 in the next 12 months. This represents a 988.4% increase from the current price of $1.16. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is MIRA Pharmaceuticals, Inc. - Common Stock's business model?

MIRA Pharmaceuticals focuses on developing innovative therapies for neurological and neuropsychiatric disorders. The company generates potential revenue through the development and commercialization of its proprietary drugs, including Ketamir-2 for depression-related conditions and MIRA-55 for anxiety and cognitive decline.

What is the highest forecasted price for MIRA MIRA Pharmaceuticals, Inc. - Common Stock?

The highest price target for MIRA is $17.75 from at , which represents a 1,430.2% increase from the current price of $1.16.

What is the lowest forecasted price for MIRA MIRA Pharmaceuticals, Inc. - Common Stock?

The lowest price target for MIRA is $7.50 from at , which represents a 546.6% increase from the current price of $1.16.

What is the overall MIRA consensus from analysts for MIRA Pharmaceuticals, Inc. - Common Stock?

The overall analyst consensus for MIRA is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.63.

How accurate are MIRA stock price projections?

Stock price projections, including those for MIRA Pharmaceuticals, Inc. - Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.